ONSPIRA THERAPEUTICS is a clinical-stage biopharmaceutical company focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Our model leverages internal, external and shared expertise to efficiently advance promising medicines against clear and validated targets where there are unmet medical needs. Patients are at the very center of what we do and our urgency is driven by our passion to make a real difference. Our team is united in the belief that we can do more for patients with rare and serious pulmonary disorders, and that these patients deserve to have active, rich and fulfilling lives.
Our lead product is a novel, inhaled interleukin-1 alpha & beta (IL-1 𝛼 & β) receptor antagonist protein under development for bronchiolitis obliterans syndrome, an often-lethal condition that occurs in patients following a lung transplant. IL-1 𝛼 & β has been shown to be a critical mediator of chronic lung inflammation and fibrosis, and IL-1 𝛼 & β genetic variants are associated with chronic lung disorders. Additional programs will focus on idiopathic pulmonary fibrosis (IPF) and other rare lung diseases.
Onspira is a NeXeption Portfolio Company. For more information, visit NeXeption.com